Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYS228 in complicated urinary tract infection
NCT03377426Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Oct 2018
- Primary completion
- Oct 2019
- Modality
- Reversible Covalent Inhibitors
- Countries
- 3
01
Overview
A Phase 2 trial of ancremonam in complicated urinary tract infection (cUTI), sponsored by Novartis. Planned start Oct 2018; status: withdrawn.
02
Drugs
ancremonam
03
Conditions
complicated urinary tract infection (cUTI)
Beyond the preview
Go deeper on NCT03377426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03377426.